Frontlight ResearchEarly access
Taking peoplePhase 3
A Study to Evaluate a New Treatment Option for Helicobacter pylori Infection Compared to First Line Treatment.
Key facts
- Who runs it
- Verisfield Single Member S.A.
- Where
- Greece17 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 420 people, planned
- Started
- 7 Jul 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Record updated
- 28 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age ≥18 years
- Diagnosed active H. pylori infection established by gastroscopy and CLO test
- No prior treatment for H. pylori infection
- Clear indication for eradication therapy
- Willingness and ability to receive the study medication in the specified dose and frequency throughout the study duration
- Willingness to provide voluntary written informed consent before any clinical trial related procedure is performed (also refers to legally authorized representatives, where applicable)
Who cannot take part
- Use of any of the following concomitant medications during participation in the study and within timeframes shorter than the required washout periods: a. Antibiotics: Within the previous 4 weeks. b. PPIs or PCABs: Within the previous 2 weeks. c. Bismuth Compounds: Within the previous 4 weeks
- History of substance or alcohol abuse within 1 year prior to the study
- Use of any of the following prohibited medications during participation in the study and within timeframes shorter than the required washout periods: a) Chronic or regular use of non-steroidal anti-inflammatory drugs (NSAIDs) and/or systemic glucocorticoids (steroids) within the past 4 weeks. b) Use of anticoagulants (e.g., warfarin, DOACs) or antiplatelet agents within the past 4 weeks, with the exception of low-dose aspirin (≤100 mg/day)
- Use of any prohibited concomitant medication with known clinically significant or serious interactions with the study treatments, as defined in this protocol (Section 9.1), in the opinion of the Investigator
- Prior gastric surgery/gastrectomy or other upper gastrointestinal surgery
- Zollinger-Ellison syndrome
- Significant organ dysfunction; severe or unstable cardiopulmonary or endocrine disease
- Gastrointestinal bleeding or related iron-deficiency anemia (IDA); Barrett’s esophagus or high-grade dysplasia; dysphagia; idiopathic thrombocytopenic purpurea (ITP)
- Cockayne Syndrome
- Hypersensitivity to any of the active substances (metronidazole, bismuth, tetracycline, amoxicillin, clarithromycin, esomeprazole, 13C-urea), to any of the excipients, to other penicillins, macrolide antibiotics, nitroimidazole derivatives, or substituted benzimidazoles. History of a severe immediate hypersensitivity reaction (e.g., anaphylaxis) to another beta-lactam agent (e.g., a cephalosporin, carbapenem, or monobactam)
- Severe comorbidity (e.g., advanced renal, hepatic, or cardiac failure) or malignancy
- Patients with hypokalaemia or hypomagnesaemia, due to the risk of prolongation of the QT interval
- Any medical condition or laboratory abnormality during theScreening Period that, in the opinion of the Investigator, is clinically significant and could interfere with the participant's abilityto be included in the study
- History of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes
- Documented or suspected atrophic gastritis, which might interfere with the urea breath test (contraindication for Helicobacter Test INFAI)
- Pregnancy or lactation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of the study is to demonstrate the non-inferiority of the fixed combination Test product compared to the standard first-line therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Multicenter, Single-Blind, Parallel-Group Phase III Non-Inferiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Metronidazole, Bismuth Oxide and Tetracycline HCl to Standard Concomitant Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori in Adults.
- Record updated
- 28 August 2026